Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common
complications affecting solid organ transplant recipients, conveying higher risks of …

This review focuses on recent advances in the field of cytomegalovirus (CMV). The 2 main
strategies for CMV prevention are prophylaxis and preemptive therapy. Prophylaxis …

Background Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …

Cytomegalovirus (CMV) is one of the most common opportunistic infections that affect the
outcome of solid organ transplantation. This updated guideline from the American Society of …

Cytomegalovirus (CMV) continues to be one of the most important pathogens that
universally affect solid organ and allogeneic hematopoietic stem cell transplant recipients …

The recent approval of letermovir marks a new era of therapy for human cytomegalovirus
(HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem …

Maribavir was approved by the US Food and Drug Administration in November 2021 for the
treatment of adult and pediatric patients with post-transplant cytomegalovirus (CMV) …

Acute and chronic rejections limit the long-term survival after lung transplant. Pulmonary
antibody-mediated rejection (AMR) is an incompletely understood driver of long-term …

Common respiratory viral infections (RVIs) are an important cause of morbidity and mortality
following solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT). 1, 2 …

Human cytomegalovirus (CMV) represents the most common opportunistic infection in liver
transplant recipients. CMV infections in post liver transplant patients cause significant …